305 filings
8-K
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
FOLD
Amicus Therapeutics Inc
5 Dec 23
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
6:03am
8-K
FOLD
Amicus Therapeutics Inc
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
FOLD
Amicus Therapeutics Inc
5 Oct 23
Termination of a Material Definitive Agreement
5:00pm
8-K
i53ij2vlrkx gc3n1k
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
hhciv5g 6rnusoo
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
rk3h7 ooq4hs3koo
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
v7ur31a
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
1cxbmgohg
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
ha86absgg1givmu
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
g3xyn
13 Jul 23
Departure of Directors or Certain Officers
5:00pm
8-K
38polrwq
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
exbbu8yyx5jc s00gyl
13 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
ns1wycy19h276iu
12 May 23
Entry into a Material Definitive Agreement
5:08pm
8-K
l87jpy15
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
7n06d
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
02emdcsps
24 Apr 23
Entry into a Material Definitive Agreement
8:44am
8-K
icvbf8k
27 Mar 23
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease
7:00am
8-K
lzgc2
1 Mar 23
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
7:01am